AI Engines For more Details: Perplexity Kagi Labs You
Cognitive Enhancement: Racetams are primarily known for their ability to enhance cognitive function. They may improve memory formation and retrieval, increase attention span, and enhance overall cognitive performance.
Neuroprotective Effects: Some racetams have demonstrated neuroprotective properties, which means they may help protect neurons from damage or degeneration. This can be beneficial in conditions involving neurodegeneration, such as Alzheimer's disease or Parkinson's disease.
Treatment of Dementia: Racetams, particularly piracetam, have been studied for their potential benefits in the treatment of dementia and age-related cognitive decline. While evidence is mixed, some studies suggest that racetams may help improve cognitive function in individuals with dementia.
Epilepsy: Levetiracetam is a racetam derivative that is primarily used as an antiepileptic medication. It is effective in the treatment of various types of seizures, including partial-onset seizures, myoclonic seizures, and tonic-clonic seizures.
Anxiety and Depression: Some research suggests that racetams may have anxiolytic (anti-anxiety) and antidepressant effects, although the evidence is limited. They may help improve mood and reduce symptoms of anxiety and depression in some individuals.
Stroke Recovery: There is some evidence to suggest that racetams, particularly piracetam, may aid in stroke recovery by improving cognitive function and motor skills in individuals who have experienced a stroke. However, more research is needed in this area.
Attention Deficit Hyperactivity Disorder (ADHD): While not commonly prescribed for ADHD, some individuals may use racetams as an alternative or adjunctive treatment for ADHD symptoms. However, the evidence supporting their efficacy in ADHD is limited.
Traumatic Brain Injury (TBI): Racetams have been studied for their potential role in the treatment of traumatic brain injury. They may help improve cognitive function and reduce cognitive deficits associated with TBI, although more research is needed to confirm their effectiveness.
Neurological Disorders: Racetams have been investigated for their potential therapeutic effects in various neurological disorders, including multiple sclerosis, autism spectrum disorders, and cognitive impairment associated with other medical conditions.
Rank | Probiotic | Impact |
---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
Taxonomy | Rank | Effect | Citations | Notation |
---|---|---|---|---|
unclassified Robinsoniella | no rank | Decreases | ⚗️ Source Study | |
unclassified Fusobacterium | no rank | Decreases | ⚗️ Source Study | |
unclassified Negativicoccus | no rank | Decreases | ⚗️ Source Study | |
Eggerthellales | order | Decreases | ⚗️ Source Study | |
Anaerofustis stercorihominis | species | Decreases | ⚗️ Source Study | |
Asaccharospora irregularis | species | Decreases | ⚗️ Source Study | |
Negativicoccus sp. S5-A15 | species | Decreases | ⚗️ Source Study | |
Paraprevotella clara | species | Decreases | ⚗️ Source Study | |
Slackia sp. NATTS | species | Decreases | ⚗️ Source Study | |
Pseudoflavonifractor capillosus | species | Decreases | ⚗️ Source Study | |
[Collinsella] massiliensis | species | Decreases | ⚗️ Source Study | |
Parvibacter caecicola | species | Decreases | ⚗️ Source Study | |
Coriobacterineae | suborder | Decreases | ⚗️ Source Study | |
Chlamydiae/Verrucomicrobia group | superphylum | Decreases | ⚗️ Source Study |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Chronic Fatigue Syndrome | 0.1 | 0.1 | |
Depression | 0.3 | 0.3 | |
ME/CFS without IBS | 0.1 | 0.1 | |
Mood Disorders | 0.3 | 0.3 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.